OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
OKYO Pharma is all set to commence a clinical trial for dry eye treatment in the US
Activation of First Clinical Trial Site in the U.S
OKYO Pharma LTD has commenced the trial process for its treatment of dry eye disease.
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
OKYO Pharma Limited (AIM:OKYO) Custom Clearance of GMP Packaged OK-101 Drug
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Limited (AIM:OKYO) Appointment to Scientific Advisory Board
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board
OKYO Pharma LTD (AIM:OKYO) Interim Results for the Six Months Ending 30 September 2022
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— Â an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
OKYO Pharma Limited (AIM:OKYO) U.S. FDA Clearance of IND Application for OK-101
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited (AIM:OKYO) OKYO to Participate at Biotech Showcase
London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to
OKYO Pharma LTD (AIM:OKYO) publicly files a registration statement with the SEC
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease
OKYO Pharma LTD (AIM:OKYO) Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-
OKYO Pharma (NASDAQ: OKYO; LSE: OKYO) Interview to Air on Bloomberg U.S. on the RedChip Money Report®
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to